Saturday, May 9, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Loop Capital Analyst Downgrades Big Lots to Sell Rating with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 12, 2024
in Breaking News
0
Retail Stock Bull Market
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

On February 12, 2024, Loop Capital analyst Anthony Chukumba made a significant move by downgrading Big Lots (NYSE: BIG) from a Hold to a Sell rating, while also revising the price target from $6 to $1. This decision reflects a pessimistic perspective on the company’s stock. While the specific reasons behind the downgrade remain undisclosed, it is likely influenced by a combination of factors including the company’s performance, prevailing industry trends, and overall market conditions. As a result, investors and stakeholders closely monitoring Big Lots may find this information valuable when contemplating their investment decisions.

Analysis of BIG Stock Performance on February 12, 2024: Concerning Trends and Potential Downward Trend

On February 12, 2024, the stock performance of BIG showed some concerning trends. The stock was trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating a potential downward trend.

The stock had dropped by $0.21, representing a 3.77% decrease, bringing the closing price down to $5.36.

In pre-market trading, the stock experienced an additional drop of $1.01, suggesting that the downward trend might continue throughout the day.

The combination of trading near the bottom of its 52-week range, being below its 200-day simple moving average, and experiencing a significant drop in both after-hours and pre-market trading indicated that BIG’s stock performance on February 12, 2024, was not favorable.

Investors and analysts would likely be closely monitoring the stock’s performance throughout the day to assess whether this downward trend persists or if there are any signs of a potential recovery. It is important to note that stock market performance can be influenced by various factors, including company-specific news, industry trends, and overall market sentiment. Therefore, it would be prudent to consider these factors and conduct further research before making any investment decisions related to BIG stock.

Analyzing BIG Stock Performance on February 12, 2024: Total Revenue Decline, Net Income Fluctuations, and EPS Analysis

Title: BIG Stock Performance on February 12, 2024: A Closer Look at the Numbers

Introduction:
On February 12, 2024, the stock performance of BIG caught the attention of investors and analysts. This article delves into the financial figures of BIG, focusing on its total revenue, net income, and earnings per share (EPS). By examining the changes in these metrics since last year and last quarter, we can gain insights into the company’s recent performance.

Total Revenue Decline:
Over the past year, BIG’s total revenue stood at $5.47 billion, marking a decline of 11.09% compared to the previous year. Furthermore, the company experienced a 9.89% decrease in total revenue since the last quarter, with figures amounting to $1.03 billion. This decline in revenue signals a challenging period for BIG.

Net Income Fluctuations:
BIG’s net income figures reveal a mixed performance. In the span of one year, the company reported a net loss of -$210.71 million, representing a substantial decrease of 218.52% compared to the previous year. However, the net income for the last quarter showed a positive turnaround, with a modest increase of 101.9% to $4.74 million. This increase in net income from the previous quarter indicates that BIG may have implemented strategic measures to improve its profitability.

Earnings per Share (EPS) Analysis:
The company’s earnings per share (EPS) figures provide additional insights into BIG’s financial performance. Over the course of one year, the EPS dropped significantly by 236.98% to -$7.30. However, in the last quarter, there was a remarkable increase of 101.89% to $0.16. This improvement in EPS suggests that BIG has taken steps to enhance its profitability and generate more value for its shareholders.

Conclusion:
BIG’s stock performance on February 12, 2024, reflected a decline in total revenue over the past year and the last quarter. The company faced challenges, resulting in an 11.09% decrease in total revenue since last year and a 9.89% decrease since the previous quarter. However, the net income and EPS figures present a more nuanced picture. While BIG experienced a significant net loss of -$210.71 million over the year, it managed to turn the tide with a 101.9% increase in net income in the last quarter. Similarly, the EPS showed a substantial improvement of 101.89% in the same period. These positive changes suggest that BIG has implemented effective strategies to enhance its profitability and generate value for its shareholders. Investors and analysts will closely monitor the company’s future financial performance to assess its ability to sustain this positive momentum.

Tags: BIG
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biopharmaceutical Markets and money (1)

Immunovant Reports Impressive Quarterly Performance and Strong Financial Position

Biotechnology Market Capitalization

Calidi Biotherapeutics Unveils Revolutionary Systemic Enveloped Oncolytic Virotherapy Platform

Tonix Pharmaceuticals Receives FDA Clearance for Phase 2 OASIS Trial of TNX102 SL for Acute Stress Disorders

Recommended

Rua Gold Stock

Rua Gold Accelerates Toward Production with Key Regulatory Push

1 month ago
Aerospace and Defense Trading online (1)

FAA and Boeing to Set Production Milestones for 737 Aircraft

2 years ago
Standard Lithium Stock

Standard Lithium Secures Key Funding Interest for Arkansas Venture

5 months ago
Voestalpine Stock

Voestalpine Shares Surge as UBS Sets Ambitious 43 Euro Price Target

6 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Airbus’s Double-Edged Spring: Record Orders Clash with Lagging Deliveries and a Mega A220 Deal

Retail Investors Storm the Private Markets While the DAX Stalls at 25,000

Xbox Chief Axes Copilot Plans as Microsoft Pivots From Gaming to Grid-Scale AI

CSG Systems Posts Blowout Q1 Earnings Even as NEC Takeover Looms

Almonty Lands a Heavyweight Investor and a New Finance Chief Just as Its Korean Mine Starts to Deliver

Sivers Semiconductors Faces a Defining May as Short Sellers Circle and Nasdaq Ambitions Intensify

Trending

When the Grid Becomes the Growth Story
Newsletter

When the Grid Becomes the Growth Story

by Stephanie Dugan
May 9, 2026
0

Dear readers, On Friday we wrote that the U.S. labor market had handed the service economy another...

The Service Economy's Payroll Shield Against a $100 Oil World

The Service Economy’s Payroll Shield Against a $100 Oil World

May 8, 2026
Kontron Stock

Kontron’s Record Order Book Masks the Cost of a Painful Restructuring

May 8, 2026
Airbus Stock

Airbus’s Double-Edged Spring: Record Orders Clash with Lagging Deliveries and a Mega A220 Deal

May 8, 2026
Retail Investors Storm the Private Markets While the DAX Stalls at 25,000

Retail Investors Storm the Private Markets While the DAX Stalls at 25,000

May 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • When the Grid Becomes the Growth Story
  • The Service Economy’s Payroll Shield Against a $100 Oil World
  • Kontron’s Record Order Book Masks the Cost of a Painful Restructuring

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com